JERSEY, Channel Islands , Jan. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced it has been named a winner in the prestigious 2021 BIG Innovation Awards presented by the Business Intelligence Group .
JERSEY, Channel Islands , Dec. 22, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that on December 21, 2020 , Ed Farrell delivered a notice of resignation from his position as the Company's Chief Operating Officer.
JERSEY, Channel Islands , Dec. 10, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that it received a request from the U.S. Food and Drug Administration (FDA) for additional testing data regarding the 510(k) application
JERSEY, Channel Islands , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray.
JERSEY, Channel Islands , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland , today announced that the Company will participate in two upcoming virtual investor conferences.
FDA Emergency Use Authorization for the MosaiQ COVID-19 antibody test received FDA 510(k) clearance for Initial MosaiQ SDS microarray and MosaiQ instrument expected before the end of CY2020 European field trial for Expanded MosaiQ IH microarray progressing; on track for CE Mark submission in Q4
JERSEY, Channel Islands, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2020 will be released before market open on Monday, Nov 2, 2020 .
JERSEY, Channel Islands, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), headquartered in Eysins, Switzerland , today announced that on September 25, 2020 , the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Quotient's COVID-19 antibody
JERSEY, Channel Islands , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (the "Company"), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 20,294,117 ordinary shares at a price to the public of $4.25
JERSEY, Channel Islands , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (the Company), a commercial-stage diagnostics company, today announced the upsize and pricing of a $75 million underwritten public offering. The Company is offering 17,647,059 ordinary shares at a price to
